News

Exercise appears to benefit people with amyotrophic lateral sclerosis (ALS) by normalizing molecular changes that occur at the junction of nerves and muscles, but by degrees that depend on the type of exercise, a study in a mouse model of ALS suggests. While running and swimming both lessened the profound molecular…

The Canadian Intellectual Property Office has approved a new patent application that will allow MediciNova to use its investigational therapy ibudilast (MN-166) for the treatment of patients with amyotrophic lateral sclerosis (ALS) in Canada. The patent covers a wide range of oral ibudilast doses in people…

AcuraStem has triggered $3 million in Phase 2 funding from its Small Business Innovation Research (SBIR) grant, which the biotechnology company will use to start the second stage of its AS-1 program. That patient-derived stem cell therapy program is aimed at…

The Phase 3 clinical trial testing BrainStorm Cell Therapeutics‘ cell therapy candidate NurOwn in amyotrophic lateral sclerosis (ALS) patients is continuing as planned after a second safety assessment by the trial’s independent Data Safety Monitoring Board (DSMB) found no reasons to stop, the company announced. The…

Health professionals in Canada are more likely to recommend stretching than strength or aerobic exercises to people with amyotrophic lateral sclerosis (ALS), a recent survey found. However, this approach isn’t supported by currently available data. The survey results were published in the journal BMC Neurology in a study titled,…

The REFINE-ALS study, an effort to identify and measure the levels of specific biomarkers in amyotrophic lateral sclerosis (ALS) patients being treated for a first time with Radicava (edaravone), has enrolled its first participant, Mitsubishi Tanabe Pharma America (MTPA) announced. This observational trial, sponsored by MTPA — which developed…

ProMIS Neurosciences is advancing its program for amyotrophic lateral sclerosis (ALS) by generating antibodies that specifically target the toxic TDP-43 clumps — a hallmark of the condition. The antibody candidates may work as therapies for both ALS and frontotemporal dementia (FTD), the company says. As a result…

Drake University’s Occupational Therapy Doctorate program is adding a new educational resource that will bring available assistive technology used in amyotrophic lateral sclerosis(ALS) to its Caregiver Learning Labs for patients and their families. The new Assistive Technology Kit, which will be used in the labs to improve…

FUS protein plays a role in the proper functioning and stability of the neuromuscular junction — the site of communication between motor nerves and muscle fibers — and mutations in this protein appear to be toxic to both motor neurons and muscle cells, causing features of amyotrophic lateral sclerosis…

The Phase 2 CENTAUR trial testing AMX0035 for amyotrophic lateral sclerosis (ALS) was designed to include patients with the most severe disease to yield the most powerful results possible, a researcher explained in a recent webinar hosted by Amylyx Pharmaceuticals, which is developing the therapy. The trial…